Zhu, Xiaoxia
Hu, Jiankang
Liu, Dongzhou
Li, Jingyang
Wu, Huaxiang
Sun, Lingyun
Dai, Lie
Tan, Chunyu
Li, Zhijun
Xiao, Zhengyu
Li, Xiaomei
Yan, Yan
Dou, Guanshen
Sun, Yuzi
Zou, Hejian http://orcid.org/0000-0001-9762-2663
Clinical trials referenced in this document:
Documents that mention this clinical trial
AB0912 IXEKIZUMAB IMPROVES SPINAL PAIN, STIFFNESS, FUNCTION, AND MOBILITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS REGARDLESS OF BASELINE INFLAMMATION STATUS
https://doi.org/10.1136/annrheumdis-2024-eular.2412
POS0801 IXEKIZUMAB IMPROVES DISEASE ACTIVITY OF RADIOGRAPHIC-AXIAL SPONDYLOARTHRITIS IN CHINESE PATIENTS IRRESPECTIVE OF BASELINE OBJECTIVE INFLAMMATION STATUS
https://doi.org/10.1136/annrheumdis-2024-eular.357
Rapid and Sustained Effect of Ixekizumab on Patient Global, Spinal Pain, Stiffness, and Fatigue in Chinese Patients with Radiographic Axial Spondyloarthritis
https://doi.org/10.1007/s40744-024-00688-9
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 31 January 2024
Accepted: 30 May 2024
First Online: 21 June 2024
Declarations
:
: Guanshen Dou, Yan Yan and Yuzi Sun are employees and shareholders of Eli Lilly and Company. Hejian Zou received research grants from Eli Lilly and Company. Xiaoxia Zhu, Jiankang Hu, Dongzhou Liu, Jingyang Li, Huaxiang Wu, Chunyu Tan, Lie Dai, Lingyun Sun, Zhijun Li, Zhengyu Xiao and Xiaomei Li have no conflicts of interest to declare in relation to this work.
: The study protocol was approved by local ethics committees and full list of the ethics review boards are available in previously published manuscript supplements []. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki and the Council of International Organizations of Medical Sciences International Ethical Guidelines. Written informed consent was obtained for all patients.